Document Type : Original Research


1 Department of Pathology, K S Hegde Medical Academy, NITTE (Deemed to be University), Deralakatte, Mangalore, Karnataka, India

2 KSHEMA Centre for Genetic Services, K S Hegde Medical Academy NITTE (Deemed to be University), Deralakatte, Mangalore, Karnataka, India

3 2. KSHEMA Centre for Genetic Services, K S Hegde Medical Academy NITTE (Deemed to be University), Deralakatte, Mangalore, Karnataka, India


Background & Objective: Breast cancer is the most common cancer in developed and developing countries. This study mainly addresses the issue of an equivocal result in IHC, which then needs further assessment if the patient has to receive targeted therapy. The study aimed to detect the expression of Her2/neu protein in breast cancer by immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) and evaluate concordance and discordance between the two methods. Also, the clinicopathological parameters in these patients were studied in association with ER, PR, HER-2, and Ki-67.
Methods: This study was conducted on 34 female carcinoma breast specimens, including core biopsies and mastectomies. Each case underwent histopathological and immunohistochemical studies for (Estrogen Receptor) ER, (Progesterone Receptor) PR, (Human Epidermal growth factor Receptor 2) HER-2, and Ki-67. In addition, FISH was done on all the samples to detect Her2 gene amplification.
Results: The overall concordance between the two tests was 79.41% while the concordance between the two tests in equivocal cases, was 14.3%. ER/PR expression and HER-2 amplification were inversely associated. Also, Ki-67 expression was not associated with the side size of the lesion, lymphovascular invasion, and lymph node metastasis. Age less than 50 at presentation and infiltrating ductal carcinoma histological type showed increased proliferation index.
Conclusion: The highest concordance between FISH and IHC was noted in IHC positive and negative cases, whereas IHC equivocal cases showed low concordance. FISH accurately determines the assessment of HER2 expressions in equivocal cases. 


Main Subjects

  1. Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al, ICMR-NCDIR-NCRP Investigator Group. Cancer statistics, 2020: Report from National Cancer Registry Programme, India. JCO Glob Oncol. 2020;1063-75. [DOI:10.1200/GO.20.00122] [PMID] [PMCID]
  2. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116(3):561-70. [DOI:10.1172/JCI27987] [PMID] [PMCID]
  3. Seol H, Lee HJ, Choi Y, Lee HE, Kim YJ, Kim JH, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol. 2012;25(7):938-48. [DOI:10.1038/modpathol.2012.36] [PMID]
  4. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immune-histochemistry and gene amplification by Fluorescence in situ hybridization. Mayo Clin Proc. 2002;77(2):148-154. [DOI:10.1016/S0025-6196(11)62329-X]
  5. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174-83. [DOI:10.1016/S1470-2045(09)70262-1]
  6. Allison KH, Hammond ME, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists guideline update. Arch Pathol Lab Med. 2020;144(5):545-63. [DOI:10.5858/arpa.2019-0904-SA] [PMID]
  7. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736-50. [DOI:10.1093/jnci/djp082] [PMID] [PMCID]
  8. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8): 1736-47. [DOI:10.1093/annonc/mdr304] [PMID] [PMCID]
  9. Kulkarni A, Kelkar DA, Parikh N, Shashidhara LS, Koppiker CB, Kulkarni M. Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer. JCO Global Oncol. 2020; 6:1052-62. [DOI:10.1200/GO.20.00054] [PMID] [PMCID]
  10. Rajan G, Culas TB, Jayalakshmy PS. Estrogen and progesterone receptor status in breast cancer: a cross-sectional study of 450 women in Kerala, South India. World J Surg Oncol. 2014;12(1):1-4. [DOI:10.1186/1477-7819-12-120] [PMID] [PMCID]
  11. Aman NA, Doukoure B, Koffi KD, Koui BS, Traore ZC, Kouyate M, et al. Immunohistochemical evaluation of Ki-67 and comparison with clinicopathologic factors in breast carcinomas. Asian Pac J Cancer Prev. 2019;20(1):73-79. [PMID] [PMCID] [DOI:10.31557/APJCP.2019.20.1.73]
  12. Abdollahi A, Sheikhbahaei S, Safinejad S, Jahanzad I. Correlation of ER, PR, HER-2 and P53 Immunoreactions with clinico-pathological features in breast cancer. Iran J Pathol. 2013;8(3):147-52.
  13. Payandeh M, Sadeghi M, Sadeghi E, Koohian AK. Comparison of IHC, FISH, ER and PR in breast cancer in Western Iran. Am J Cancer Prevent. 2014;2(2):37-41. [DOI:10.12691/ajcp-2-2-4]
  14. Kumar RV, Panwar D, Amirtham U, Premalata CS, Gopal C, Narayana SM, et al. Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India. South Asian J Cancer. 2018;7(01):07-10. [DOI:10.4103/sajc.sajc_211_17] [PMID] [PMCID]
  15. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-23. [PMID] [PMCID] [DOI:10.1093/annonc/mdt303]
  16. Patil A, Nigudgi S, Karangadan S, Andola SK. Association of Ki67 expression with clinicopathological parameters and molecular classification in invasive breast carcinomas. Indian J Pathol Oncol. 2019;6(2):207-12. [DOI:10.18231/j.ijpo.2019.040]
  17. Manjunath S, Prabhu JS, Kaluve R, Correa M, Sridhar TS. Estrogen receptor negative breast cancer in India: do we really have higher burden of this subtype?. Indian J Surg Oncol. 2011;2(2):122-5. [DOI:10.1007/s13193-011-0072-8] [PMID] [PMCID]
  18. Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V, et al. Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is?. Indian Journal of Pathology and Microbiology. 2009;52(2):171-174. [DOI:10.4103/0377-4929.48909] [PMID]
  19. Iqbal BM, Buch A. Hormone receptor (ER, PR, HER2/neu) status and proliferation index marker (Ki-67) in breast cancers: Their onco-pathological correlation, shortcomings and future trends. Medical Journal of Dr. DY Patil University. 2016;9(6):674-679. [DOI:10.4103/0975-2870.194180]
  20. Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. Medicine. 2016;95(35):1-6. [PMID] [PMCID] [DOI:10.1097/MD.0000000000004614]
  21. Panjwani P, Epari S, Karpate A, Shirsat H, Rajsekharan P, Basak R, et al. Assessment of HER-2/neu status in breast cancer using Fluorescence in situ hHybridization& immunohistochemistry: Experience of a tertiary cancer referral centre in India. Indian J Med Res. 2010;132(2):287-94.
  22. Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P, et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian journal of cancer. 2011;48(4):391-396. [DOI:10.4103/0019-509X.92245] [PMID]
  23. Patel DM, Parmar RA, Varma PK, Ladani DC, Patel PS, Trivedi PJ, et al. Assessment of HER2/Neu level using molecular cytogenetic in breast cancer: A study at a regional cancer center. J Genet Mutat. 2018;1:21-4.
  24. Mostafa NA, Eissa SS, Belal DM, Shoman SH. Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining. Journal of the Egyptian National Cancer Institute. 2011;23(1):41-6. [DOI:10.1016/j.jnci.2011.07.006] [PMID]
  25. Siadati S, Sharbatdaran M, Nikbakhsh N, Ghaemian N. Correlation of ER, PR and HER-2/Neu with other prognostic factors in infiltrating ductal carcinoma of breast. Iran J Pathol. 2015;10 (3):221.
  26. Fusun T, Semsi A, Cem U, Mevlut T, Zafer K, Kazim U, et al. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients. Exp Oncol. 2005; 27(2):145-9.
  27. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539-52. [PMID] [PMCID] [DOI:10.1007/s10549-013-2560-8]
  28. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of Fluorescence in situ hybridizationand immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17(7):1974-1982. [DOI:10.1200/JCO.1999.17.7.1974] [PMID]
  29. Sui W, Ou M, Chen J, Wan Y, Peng H, Qi M, et al. Comparison of immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer. World J Surg Oncol. 2009;7(1):1-6. [PMID] [PMCID] [DOI:10.1186/1477-7819-7-83]
  30. Bogdanovska-Todorovska M, Kostadinova-Kunovska S, Jovanovik R, Krsteska B, Kondov G, Kondov B, et al. Correlation of immunohistochemistry and Fluorescence in situ hybridizationfor HER-2 assessment in breast cancer patients: single centre experience. Open Access Maced J Med Sci. 2018;6(4):593. [DOI:10.3889/oamjms.2018.124] [PMID] [PMCID]
  31. Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and Fluorescence in situ hybridization comparison of results and correlation with survival. Mol Diagn Ther. 2000;5(3):199-207. [DOI:10.2165/00066982-200005030-00006]